8-K: Jaguar Health Implements 1-for-60 Reverse Stock Split and Amends At-the-Market Offering Agreement
8-K Filing
Jaguar Health has enacted a 1-for-60 reverse stock split and amended its at-the-market offering agreement, removing the previous $75 million limit.
Summary
- Jaguar Health, Inc. has implemented a one-for-sixty reverse stock split of its common stock, effective May 23, 2024.
- This action was taken to support the company's compliance with Nasdaq listing standards and potentially attract institutional investors.
- The company also amended its At-the-Market Offering Agreement with Ladenburg Thalmann & Co. Inc., removing the previous $75 million limit on share issuances.
- The company filed a prospectus supplement with the SEC in connection with the offer and sale of shares under the amended agreement.
- The reverse stock split will reduce the number of outstanding shares and proportionately increase the conversion and exercise prices of outstanding stock options and warrants.
- Stockholders who would have received fractional shares will receive a cash payment instead.
Sentiment
Score: 5
Explanation: The document contains both positive and negative elements. The reverse stock split is a necessary action to maintain listing compliance, but it can be perceived negatively by investors. The removal of the limit on the ATM offering is positive for capital raising flexibility, but also indicates a need for capital.
Positives
- The reverse stock split is intended to support compliance with Nasdaq listing standards.
- The reverse stock split may make the company's share price more attractive to institutional investors.
- The removal of the $75 million limit on the At-the-Market Offering Agreement provides the company with more flexibility in raising capital.
Negatives
- The reverse stock split reduces the number of outstanding shares, which may be perceived negatively by some investors.
- The reverse stock split increases the conversion and exercise prices of outstanding stock options and warrants, which may be unfavorable to holders of these instruments.
Risks
- The reverse stock split may not achieve the desired effect of attracting institutional investors.
- The company's ability to raise capital through the amended At-the-Market Offering Agreement is subject to market conditions and investor demand.
- The company's stock price may be volatile following the reverse stock split.
Future Outlook
The company expects its common stock to begin trading on a split-adjusted basis on May 23, 2024, and believes the reverse stock split may make its share price more attractive to institutional investors.
Management Comments
- Lisa Conte, Jaguar's president and CEO, stated that the reverse stock split will support the company's compliance with Nasdaq listing standards and provide an opportunity to achieve a share price and outstanding share count that is more attractive to institutional investors.
Industry Context
Reverse stock splits are often used by companies to regain compliance with stock exchange listing requirements, particularly when their share price has fallen below a minimum threshold. The amendment to the at-the-market offering agreement is a common mechanism for companies to raise capital in a flexible manner.
Comparison to Industry Standards
- Reverse stock splits are a common strategy for companies facing delisting from exchanges like Nasdaq, similar to actions taken by other small-cap biotech firms facing similar challenges.
- The use of an at-the-market offering agreement is a standard practice for companies seeking to raise capital opportunistically, comparable to strategies employed by other companies in the pharmaceutical and biotech sectors.
- The specific ratio of 1-for-60 is within the range of reverse stock splits seen in the market, although the exact ratio is often determined based on the specific circumstances of the company.
Stakeholder Impact
- Shareholders will experience a reduction in the number of shares they own due to the reverse stock split.
- Shareholders who would have received fractional shares will receive a cash payment instead.
- The reverse stock split may impact the company's ability to attract institutional investors.
- The amended At-the-Market Offering Agreement may lead to dilution of existing shareholders if new shares are issued.
Next Steps
- The company's common stock will begin trading on a split-adjusted basis on May 23, 2024.
- Stockholders who hold stock certificates will receive instructions from Equiniti Trust Company, LLC regarding the exchange of their certificates.
- The company may issue and sell shares through Ladenburg Thalmann & Co. Inc. under the amended At-the-Market Offering Agreement.
Key Dates
| Date | Description |
|---|---|
| 2013-06-06 | Date of filing of the Corporation's original Certificate of Incorporation with the Secretary of State of the State of Delaware under the name Jaguar Animal Health, Inc. |
| 2021-12-10 | Date of the original At the Market Offering Agreement between Jaguar Health and Ladenburg Thalmann & Co. Inc. |
| 2022-02-02 | Date of the first amendment to the At the Market Offering Agreement. |
| 2024-03-15 | Date the company filed its definitive proxy statement on Schedule 14A relating to the Special Meeting with the SEC. |
| 2024-04-09 | Date of the special meeting of stockholders where the reverse stock split was approved. |
| 2024-04-22 | Date the company filed its registration statement on Form S-3 with the SEC. |
| 2024-05-01 | Date the registration statement on Form S-3 was declared effective. |
| 2024-05-17 | Date the company filed the Eighth Amendment to the Certificate of Incorporation with the Secretary of State of Delaware and the date of the press release announcing the reverse stock split. |
| 2024-05-23 | Date the reverse stock split became effective, the date of the second amendment to the At the Market Offering Agreement, and the date the company filed the prospectus supplement with the SEC. |
| 2025-01-22 | Latest date for the Board to determine the exact ratio of the reverse stock split. |
Keywords
reverse stock split, at-the-market offering, common stock, Ladenburg Thalmann, Nasdaq, share issuance, capital raise, stock options, warrants
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.